Project Grant R01DA061433
Award Date 5/15/24
Completion Date 3/31/29
Dollars Obligated $1.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Wauwatosa, WI 53226, USA
Similar Awards
- Federal Project Grant Award Summary Oregon Health & Science University received a $736,713 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective February 15, 2026, with a completion date of November 30, 2030. The award funds the Psilocybin Research and Implementation Study for Mental Health and Substance Use (PRISM), designed to evaluate the safety and effectiveness of state-regulated psilocybin...
- Federal Project Grant Award Summary The Medical University of South Carolina received a $139,851 Project Grant award from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) effective October 10, 2025, with a completion date of April 30, 2028. This award supports research investigating the therapeutic potential of psilocybin in treating stress-induced relapse in patients with opioid use disorder (OUD) and comorbid post-traumatic stress disorder...
- Federal Project Grant Award Summary Princeton University received a $246,000 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded June 15, 2025, with completion targeted for May 31, 2027. The grant supports fundamental neuroscience research investigating the systems-level brain mechanisms underlying psilocybin's therapeutic potential for treating anxiety, depression, addiction, pain, and illness-associated...
- Federal Grant Award Summary New York University School of Medicine is conducting a clinical research project funded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242). The $871,225 project grant, awarded March 1, 2026, with a completion date of November 30, 2030, investigates psilocybin as a novel therapeutic intervention for residual anhedonia in patients currently taking selective serotonin reuptake inhibitors (SSRIs). The research...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded Myosin Therapeutics Inc. a $2,916,991 Project Grant on April 1, 2025 to support a first-in-human double-blind, placebo-controlled single ascending dose (SAD) Phase 1B clinical trial of their novel therapeutic agent MT-110 for reducing methamphetamine use disorder (MUD). With an estimated 4 million people in the U.S. affected by MUD and limited treatment options available, the...
- Federal Project Grant Award Summary Harvard Medical School received a $712,500 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) effective September 1, 2025, through May 31, 2030. This research project investigates the mechanistic role of visual processing areas in the brain's response to illicit drugs and their interaction with social behavior using nonhuman primate models. The award supports electrophysiological...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The University of Kentucky Research Foundation a $1.255 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct human laboratory research translating preclinical findings on troriluzole as a pharmacotherapy for methamphetamine use disorder (MUD). The award, obligated on April 15, 2025, with a completion date of February 28, 2029, supports a clinical study evaluating...
- Summary of Federal Cooperative Agreement Award Virginia Commonwealth University received a $643,019 Cooperative Agreement award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a proof-of-concept randomized controlled trial evaluating psilocybin-assisted treatment for cocaine use disorder (CocUD). The award, effective July 15, 2025, through June 30, 2027, supports research combining psilocybin with psychedelic...
- Federal Grant Award Summary The University of Oregon received a $406,051 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective June 15, 2025 through May 31, 2027. This research award supports a genetic analysis study investigating psychoplasticity in Caenorhabditis elegans to advance understanding of how psychedelic compounds may treat intractable psychiatric diseases, including depression,...
- The National Institute on Drug Abuse (NIDA) awarded the University of Texas Health Science Center at Houston $2,085,384 on June 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a pilot mechanistic study investigating semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), as a potential treatment for cocaine use disorder (CUD). This R01 Stage IIA project, which will conclude February 28, 2029, will generate proof-of-concept evidence demonstrating...